Pharvaris Closes $132.3M Public Offering, Including Full Over-Allotment Exercise
PHVS has more than doubled off its 52-week low of $14.585 on elevated volume (3.7× avg).
Summary
Pharvaris N.V. has successfully closed its underwritten public offering, raising approximately $132.3 million in gross proceeds, which includes the full exercise of the over-allotment option.
Key Events · Financing and Capital Events · PHVS
-
Offering Closed
Pharvaris N.V. completed its underwritten public offering on May 11, 2026, following the underwriting agreement dated May 8, 2026.
-
Substantial Capital Raised
The company raised approximately $132.3 million in gross proceeds by selling 4,455,863 ordinary shares at a public offering price of $29.68 per share. Net proceeds are expected to be approximately $124 million.
-
Full Over-Allotment Exercise
The underwriters fully exercised their option to purchase an additional 581,199 ordinary shares, indicating strong demand for the offering.
-
Funding for Clinical Programs and Commercialization
Proceeds will primarily fund research and development expenses for late-stage clinical programs, expand the U.S. sales and marketing team, and cover general corporate purposes.
Analysis · PHVS · Life Sciences
This filing confirms the successful closing of a substantial public offering, including the full exercise of the underwriters' over-allotment option, which increased the total capital raised to approximately $132.3 million. This significant funding provides crucial runway for Pharvaris's late-stage clinical programs and commercialization efforts, especially following recent positive clinical data. The strong demand, evidenced by the full over-allotment exercise, indicates investor confidence in the company's prospects despite the dilutive nature of the offering.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.9% of the 1030 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHVS was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.59 to $31.65. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.